Abstract：Objective: To investigate the correlation between the levels of serum glucagon like peptide-1 (GLP-1) and intercellular adhesion factor-1 (ICAM-1) and the degree of nerve injury in patients with acute cerebral infarction (ACI). Methods: A total of 67 patients with ACI in our hospital from October 2018 to December 2019 were selected as the research objects, according to National Institute of Health stroke scale (NIHSS) score, ACI patients were divided into 23 cases in mild group (NIHSS score < 5), 28 cases in moderate group (5 ≤ NIHSS score < 20), and 16 cases in severe group (NIHSS score ≥ 20), and 50 healthy volunteers in our hospital were randomly selected as the control group. The levels of serum GLP-1, ICAM-1, S100 calcium binding protein B (S100B) and neuron specific enolase (NSE) were detected by enzyme-linked immunosorbent assay and compared between the study group and the control group, the serum index levels of each groups were compared. Pearson method was used to analyze the correlation of serum GLP-1, ICAM-1 levels with S100B, NSE levels and NIHSS score. Results: The level of serum GLP-1 in the study group was significantly lower than that in the control group (P<0.05), and the levels of ICAM-1, S100B and NSE in the study group were significantly higher than those in the control group (P<0.05); compared with those in mild group, the level of GLP-1 in moderate group and severe group was significantly lower (P<0.05), and the levels of ICAM-1, S100B and NSE were significantly higher (P<0.05); compared with those in the moderate group, the level of GLP-1 in the severe group was significantly lower (P<0.05), and the levels of ICAM-1, S100B and NSE were significantly higher (P<0.05); compared with before treatment, the level of GLP-1 in ACI patients increased significantly after treatment (P<0.05), the levels of ICAM-1, S100B and NSE and NIHSS score decreased significantly (P<0.05); Pearson results showed that serum GLP-1 level was negatively correlated with ICAM-1, S100B, NSE level and NIHSS score (all P<0.05), and ICAM-1 level was positively correlated with S100B, NSE level and NIHSS score (all P<0.05). Conclusion: With the aggravation of nerve injury in patients with ACI, the level of serum GLP-1 gradually decreases, and the level of ICAM-1 gradually increases, they are closely related to the levels of S100B and NSE, and may be used as potential biological indicators of nerve injury in patients with ACI.
[1] 郭连峰,牟娜,刘兆玮,等.老年急性脑梗死患者血清CRP,VEGF及YKL-40水平动态变化及相关性[J].中国老年学杂志,2020,40(1):14~19. [2] Almutairi M,Al Batran R,Ussher JR.Glucagon-like peptide-1 receptor action in the vasculature[J].Peptides,2019,111(1):26~32. [3] Insuela DBR,Carvalho VF.Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds[J].Eur Pharmacol,2017,812(1):64~72. [4] Jiang D,Wang Y,Zang Y,et al.Neuroprotective effects of rhGLP-1 in diabetic rats with cerebral ischemia/reperfusion injury[J].Drug Dev Res,2016,77(3):124~133. [5] Nepal G,Yadav JK,Kong Y.Association between K469E polymorphism of ICAM-1 gene and susceptibility of ischemic stroke:An updated meta-analysis[J].Mol Genet Genomic Med,2019,7(7):1~9. [6] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666~682. [7] Yildirim Simsir I,Soyaltin UE,Cetinkalp S.Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease[J].Diabetes Metab Syndr,2018,12(3):469~475. [8] Grieco M,Giorgi A,Gentile MC,et al.Glucagon-like peptide-1:a focus on neurodegenerative diseases[J].Front Neurosci,2019,13(1):1~10. [9] Cai HY,Yang JT,Wang ZJ,et al.Lixisenatide reduces amyloid plaques,neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease[J].Biochem Biophys Res Commun,2018,495(1):1034~1040. [10] Shan Y,Tan S,Lin Y,et al.The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke[J].Neuroinflammation,2019,16(1):1~14. [11] Lin QY,Lang PP,Zhang YL,et al.Pharmacological blockage of ICAM-1 improves angiotensin Ⅱ-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes[J].Am Physiol Heart Circ Physiol,2019,317(6):1301~1311. [12] Lino DOC,Freitas IA,Meneses GC,et al.Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure[J].Braz Med Biol Res,2019,52(12):1~6. [13] 陈龙剑,凌丽,何龙.脑梗死患者脑微出血与血管内皮损伤标志物ICAM-1,eNOS,sTM的相关性研究[J],医学研究与教育,2019,36(3):27~32. [14] Lasek-Bal A,Jedrzejowska-Szypulka H,Student S,et al.The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis[J].Physiol Pharmacol,2019,70(2):1~9. [15] Topuzova MP,Alekseeva TM,Panina EB,et al.The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke[J].Zh Nevrol Psikhiatr Im S S Korsakova,2019,119(8):53~62.
2021, Vol. 27 
冀公网安备13080202000677号